Pharma

  • AI brain
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all

    The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.

    By • July 1, 2025
  • Doctor holding patient's hands
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    First 90 Days

    A biopharma doubles down on diversity goals through a newly created position

    Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.

    By Alexandra Pecci • July 1, 2025
  • drug shopping cart Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Commercialization, marketing and social media

    As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

    By PharmaVoice staff
  • Makary FDA
    Image attribution tooltip
    Andrew Harnik via Getty Images
    Image attribution tooltip

    FDA’s new mission to speed drug reviews

    FDA Commissioner Dr. Marty Makary is leading a handful of controversial new initiatives to make the drug review process more streamlined.

    By • June 30, 2025
  • Gilead sign
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    3 of the year’s most notable FDA nods

    The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.

    By • June 27, 2025
  • A person in a business suit looks past two other people standing with their backs to the camera.
    Image attribution tooltip
    Elijah Nouvelage via Getty Images
    Image attribution tooltip

    CDC panel, newly remade by RFK Jr., questions vaccine evidence

    New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.

    By Delilah Alvarado • June 26, 2025
  • An entrance to a National Institutes of Health building is lit by the sun on a clear day.
    Image attribution tooltip
    Grandbrothers via Getty Images
    Image attribution tooltip

    Biopharma is on edge about NIH funding cuts and what the future holds for research

    Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.

    By • June 26, 2025
  • Narcotic Brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After myriad failures, a new wave of ALS drugs approaches

    Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.

    By • June 25, 2025
  • hand grave
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biogen scores Cannes Festival win with dark humored campaign

    The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.

    By Alexandra Pecci • June 24, 2025
  • pills lie instead of eyes on a one hundred dollar bill in close-up.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

    More drugs surpassed $10 billion in revenue last year than ever before.

    By • June 23, 2025
  • Retro microphones for press conference or interview and old TV on table front gradient aquamarine background
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    Is DTC pharma advertising coming to an end?

    A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

    By • June 18, 2025
  • man in a navy suit with a red tie sits hands crossed at a desk with a microphone
    Image attribution tooltip
    Kayla Bartkowski via Getty Images
    Image attribution tooltip

    FDA to speed reviews for drugs supporting ‘national interests’

    A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

    By Jonathan Gardner • June 18, 2025
  • diversity hands pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    How a patient group tackled research diversity for one disease and triggered change for pharma

    A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

    By • June 17, 2025
  • Sarah Sanders in white stands at podium with three American flags in the background
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    Locked in a federal stalemate, states take PBM reform into their own hands

    Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.

    By • June 16, 2025
  • doctor piggy bank 340B
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Will pharma finally score a policy win for 340B?

    The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

    By Kelly Bilodeau • June 16, 2025
  • Maya Martinez-Davis
    Image attribution tooltip
    Permission granted by Michael Moenning, Northlight Studio
    Image attribution tooltip
    Profile

    A day in the life of GSK’s U.S. president

    How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

    By • June 13, 2025
  • Syringes biotech
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Can ‘reputational pull’ save biotech from pharma’s image problem?

    A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

    By • June 12, 2025
  • Capitol Hill lit up at night
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Pharma’s wins and losses in the budget bill

    Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

    By • June 11, 2025
  • Ronny Gal, chief strategy and growth officer, Novartis
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip
    Profile

    The former Wall Street analyst shaping Novartis’ big-picture strategy

    Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

    By • June 10, 2025
  • Road sign symbolizing decision between vaccine or no vaccine
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    COVID vax restrictions may not hamper uptake — but the market is still under pressure

    If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

    By Alexandra Pecci • June 10, 2025
  • Four faces
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip
    Sponsored by Pfizer

    The mindfulness of medicine development: How scientists are driving the next wave of medical innovations

    For millions of patients, the development of a new treatment or vaccine can be life-changing.

    June 9, 2025
  • A sign with the Roche logo stands in front of a tall building.
    Image attribution tooltip
    Permission granted by Roche
    Image attribution tooltip

    The biggest obesity deals of 2025 so far

    Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

    By • June 9, 2025
  • Enhertu
    Image attribution tooltip
    Permission granted by Daiichi Sankyo
    Image attribution tooltip

    With ADCs on the rise, drugmakers embrace a new oncology pillar

    A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

    By • June 6, 2025
  • A person in a dark business suit sits at a desk with a microphone.
    Image attribution tooltip
    Anna Moneymaker via Getty Images
    Image attribution tooltip

    FDA’s Elsa AI is here, and the industry has questions

    The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.  

    By • June 5, 2025
  • sad face bag
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biotech CEO confidence hits rock bottom amid policy shifts

    A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

    By • June 4, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi to acquire Blueprint for up to $9.5B

    The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

    By Jacob Bell • June 3, 2025